This is a preview of subscription content, log in via an institution to check access.
Reference
Van Wilder P, et al. Impact of health technology assessment and managed entry schemes on reimbursement decisions of centrally authorised medicinal products in Belgium. European Journal of Clinical Pharmacology : 15 Mar 2019. Available from: URL: http://doi.org/10.1007/s00228-019-02665-6
Rights and permissions
About this article
Cite this article
Managed entry schemes impact reimbursement decisions. PharmacoEcon Outcomes News 825, 23 (2019). https://doi.org/10.1007/s40274-019-5789-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5789-6